Anti-CD123 nano antibody and application thereof

A nanobody and chimeric antigen receptor technology, applied in the field of biomedicine, can solve problems such as failure to achieve ideals, and achieve high affinity effects
CN112480258AActive Publication Date: 2021-03-12HUADAO SHANGHAI BIOPHARMA CO LTD
4 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HUADAO SHANGHAI BIOPHARMA CO LTD
Publication Date
2021-03-12

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides an anti-CD123 nano antibody and application thereof. The nano antibody comprises a heavy chain variable region, wherein the heavy chain variable region comprises CDR1 as shown in SEQ ID NO: 1, CDR2 as shown in SEQ ID NO: 2 and CDR3 as shown in SEQ ID NO: 3. The antibody screened from the camel VHH immune library has CDR regions shown as SEQ ID NO: 1-3, the nano antibody formed by combining the antibody with different framework regions FR has strong affinity with CD123, so that the constructed chimeric antigen receptor and chimeric antigen receptor immune cells have remarkable cytotoxicity on CD123 positive cells, and have wide application prospects in the field of tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of biomedicine, and relates to anti-CD123 nanometer antibody and application thereof. Background technique

[0002] More than 30 years ago, the "3+7" regimen (daunorubicin chemotherapy for 3 days combined with cytarabine chemotherapy for 7 days) brought about 60% of AML patients into remission and became the standard induction regimen for children and adults with acute leukemia . In the 1990s, clinical experts began to focus on post-remission treatment options and their benefits, and a large number of studies were conducted, including high-dose cytarabine chemotherapy or hematopoietic stem cell transplantation (HSCT). Although the remission rate and overall survival rate of acute leukemia in children have reached greater than 90% and 60%, respectively, existing treatment options are still limited to anthracyclines, nucleoside analogs, and intensive post-remission therapy. In order to improve the prognosis ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More